Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease

Shih Ming Huang, Wei Ting Liao, Chiou Feng Lin, H. Sunny Sun, Nan Haw Chow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: To reduce intraoperative and postoperative complications, using Lugol solution to preoperatively prepare patients with Graves' disease has (1) rapidly reduced the severity of thyrotoxicosis and (2) reduced the vascularity of the thyroid gland. The vascularity reduction normally accompanies reducing the severity of thyrotoxicosis. However, the effects and mechanism of Lugol solution for reducing blood flow have not been well investigated in the patients with euthyroid (normally functioning thyroid) Graves' disease. Methods: Twenty-five patients with euthyroid Graves' disease being preoperatively treated with Lugol solution for 10 days were measured, at baseline and on the operative day, for (1) superior thyroid artery blood flow; (2) systemic angiogenic factor (VEGF); and (3) systemic inflammatory factor [interleukin (IL)-16]. Results: All three parameters were significantly (p < 0.0001) lower after 10 days of Lugol solution treatment. The average reductions were blood flow: 60 % (0.294 vs. 0.117 L/min), serum VEGF: 55 % (169.8 vs. 76.7 pg/mL), and serum IL-16: 50 % (427.2 vs. 214.2; pg/mL). Conclusion: Lugol solution significantly reduced thyroid arterial blood flow, VEGF, and IL-16, even in patients with euthyroid Graves' disease. We recommend routine preoperative Lugol solution treatment for all patients with Graves' disease.

Original languageEnglish
Pages (from-to)505-509
Number of pages5
JournalWorld Journal of Surgery
Volume40
Issue number3
DOIs
Publication statusPublished - Mar 1 2016
Externally publishedYes

Fingerprint

Graves Disease
Thyroid Gland
Interleukin-16
Vascular Endothelial Growth Factor A
Thyrotoxicosis
Angiogenesis Inducing Agents
Thyroid Diseases
Intraoperative Complications
Serum
Lugol's solution
Arteries
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease. / Huang, Shih Ming; Liao, Wei Ting; Lin, Chiou Feng; Sun, H. Sunny; Chow, Nan Haw.

In: World Journal of Surgery, Vol. 40, No. 3, 01.03.2016, p. 505-509.

Research output: Contribution to journalArticle

@article{411e3e1deb2e4444b4d06f573b35e7fc,
title = "Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease",
abstract = "Background: To reduce intraoperative and postoperative complications, using Lugol solution to preoperatively prepare patients with Graves' disease has (1) rapidly reduced the severity of thyrotoxicosis and (2) reduced the vascularity of the thyroid gland. The vascularity reduction normally accompanies reducing the severity of thyrotoxicosis. However, the effects and mechanism of Lugol solution for reducing blood flow have not been well investigated in the patients with euthyroid (normally functioning thyroid) Graves' disease. Methods: Twenty-five patients with euthyroid Graves' disease being preoperatively treated with Lugol solution for 10 days were measured, at baseline and on the operative day, for (1) superior thyroid artery blood flow; (2) systemic angiogenic factor (VEGF); and (3) systemic inflammatory factor [interleukin (IL)-16]. Results: All three parameters were significantly (p < 0.0001) lower after 10 days of Lugol solution treatment. The average reductions were blood flow: 60 {\%} (0.294 vs. 0.117 L/min), serum VEGF: 55 {\%} (169.8 vs. 76.7 pg/mL), and serum IL-16: 50 {\%} (427.2 vs. 214.2; pg/mL). Conclusion: Lugol solution significantly reduced thyroid arterial blood flow, VEGF, and IL-16, even in patients with euthyroid Graves' disease. We recommend routine preoperative Lugol solution treatment for all patients with Graves' disease.",
author = "Huang, {Shih Ming} and Liao, {Wei Ting} and Lin, {Chiou Feng} and Sun, {H. Sunny} and Chow, {Nan Haw}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00268-015-3298-8",
language = "English",
volume = "40",
pages = "505--509",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Effectiveness and Mechanism of Preoperative Lugol Solution for Reducing Thyroid Blood Flow in Patients with Euthyroid Graves' Disease

AU - Huang, Shih Ming

AU - Liao, Wei Ting

AU - Lin, Chiou Feng

AU - Sun, H. Sunny

AU - Chow, Nan Haw

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: To reduce intraoperative and postoperative complications, using Lugol solution to preoperatively prepare patients with Graves' disease has (1) rapidly reduced the severity of thyrotoxicosis and (2) reduced the vascularity of the thyroid gland. The vascularity reduction normally accompanies reducing the severity of thyrotoxicosis. However, the effects and mechanism of Lugol solution for reducing blood flow have not been well investigated in the patients with euthyroid (normally functioning thyroid) Graves' disease. Methods: Twenty-five patients with euthyroid Graves' disease being preoperatively treated with Lugol solution for 10 days were measured, at baseline and on the operative day, for (1) superior thyroid artery blood flow; (2) systemic angiogenic factor (VEGF); and (3) systemic inflammatory factor [interleukin (IL)-16]. Results: All three parameters were significantly (p < 0.0001) lower after 10 days of Lugol solution treatment. The average reductions were blood flow: 60 % (0.294 vs. 0.117 L/min), serum VEGF: 55 % (169.8 vs. 76.7 pg/mL), and serum IL-16: 50 % (427.2 vs. 214.2; pg/mL). Conclusion: Lugol solution significantly reduced thyroid arterial blood flow, VEGF, and IL-16, even in patients with euthyroid Graves' disease. We recommend routine preoperative Lugol solution treatment for all patients with Graves' disease.

AB - Background: To reduce intraoperative and postoperative complications, using Lugol solution to preoperatively prepare patients with Graves' disease has (1) rapidly reduced the severity of thyrotoxicosis and (2) reduced the vascularity of the thyroid gland. The vascularity reduction normally accompanies reducing the severity of thyrotoxicosis. However, the effects and mechanism of Lugol solution for reducing blood flow have not been well investigated in the patients with euthyroid (normally functioning thyroid) Graves' disease. Methods: Twenty-five patients with euthyroid Graves' disease being preoperatively treated with Lugol solution for 10 days were measured, at baseline and on the operative day, for (1) superior thyroid artery blood flow; (2) systemic angiogenic factor (VEGF); and (3) systemic inflammatory factor [interleukin (IL)-16]. Results: All three parameters were significantly (p < 0.0001) lower after 10 days of Lugol solution treatment. The average reductions were blood flow: 60 % (0.294 vs. 0.117 L/min), serum VEGF: 55 % (169.8 vs. 76.7 pg/mL), and serum IL-16: 50 % (427.2 vs. 214.2; pg/mL). Conclusion: Lugol solution significantly reduced thyroid arterial blood flow, VEGF, and IL-16, even in patients with euthyroid Graves' disease. We recommend routine preoperative Lugol solution treatment for all patients with Graves' disease.

UR - http://www.scopus.com/inward/record.url?scp=84957431761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957431761&partnerID=8YFLogxK

U2 - 10.1007/s00268-015-3298-8

DO - 10.1007/s00268-015-3298-8

M3 - Article

VL - 40

SP - 505

EP - 509

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 3

ER -